PPARδ raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-05-01. Anything still debated is marked as such rather than presented as settled.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human therapeutic use | No marketing authorization identified in major jurisdictions. |
| Anti-doping class | PPARδ agonist; hormone and metabolic modulators | Listed on the WADA Prohibited List. |
| Common test matrix | Urine | Also blood and tissue in research settings. |
| Typical analytical method | LC-MS/MS | Targets parent compound and metabolites. |
| Major safety signal | Tumor findings in rodents | Human relevance not established; limited human data. |
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
== Sustainability == Hetero reports its ESG performance annually with reference to the Global Reporting Initiative (GRI), the Sustainability Accounting Standards Board( SASB), and the UN Global Compact. Environment Hetero leads its environment strategy with the stated goal of reaching net zero emissions by 2045. Interim environmental targets include 25% reduction in Scope 1 and Scope 2 emissions by 2030 (with 2022 as a baseline), a 30% increase in the use of renewable energy by 2030, and becoming a Zero Waste to Landfill company in the same year. According to the company’s FY2024-2025 Sustainability report, the company’s Scope 1 emissions were 3,12,435 tCO₂e and Scope 2 emissions were 2,95,020 tCO₂e, resulting in total Scope 1 and Scope 2 emissions of 6,07,455 tCO₂e. Emissions intensity for the year stood at 3.09 tCO₂e per million INR revenue, while biogenic emissions amounted to 72425 tCO₂e. The company also completed its first Scope 3 inventory, covering 13 categories and totalling 1,253,550 tCO₂e. 20% of Hetero’s total energy consumption came from renewable sources. The company recycled 343849 kilolitres of wastewater through Zero Liquid Discharge systems, and recycled 100% of non-hazardous waste, resulting in two sites (Annora and Jeedimetla) receiving Zero Waste to Landfill certification. Social Hetero’s social approach revolves around workforce wellbeing, diversity, inclusion, and occupational safety. As of FY2024-25, Hetero employed 18292 people directly and 10355 people through contract. Women made up 13.63% of direct workforce and 19.28% of contract workers.
==== Reoxygenation of intolerant animals ==== When oxygen re-enters the system, animals are faced with a different set of problems. Since ATP was used up during the anoxic period, it leads to a lack of ADP within the system. This is due to ADP's natural degradation into AMP, resulting in ADP being drained from the system. With no ADP in the system, Complex V is unable to start, meaning the protons will not flow through it to enter the matrix. Due to Complex V's reversal during anoxia, the proton gradient has become hyperpolarized (where the proton gradient is highly positively charged). Another factor in this problem is that succinate built up during anoxia, so when oxygen is reintroduced, succinate donates electrons to Complex II. The hyperpolarized gradient and succinate buildup leads to reverse electron transport, causing oxidative stress, which can lead to cellular damage and diseases.
Ferdinand's actions constituted a definitive de facto break both with the autonomous governments, which had not yet declared formal independence, and with the effort of Spanish liberals to create a representative government that would fully include the overseas possessions. Such a government was seen as an alternative to independence by many in New Spain, Central America, the Caribbean, Quito, Peru, Upper Peru and Chile. Yet the news of the restoration of the "Ancien Régime" did not initiate a new wave of juntas, as had happened in 1809 and 1810, with the notable exception of the establishment of a junta in Cuzco demanding the implementation of the Spanish Constitution. Instead most Spanish Americans were moderates who decided to wait and see what would come out of the restoration of normalcy. In fact, in areas of New Spain, Central America and Quito, governors found it expedient to leave the elected constitutional ayuntamientos in place for several years to prevent conflict with the local society. Liberals on both sides of the Atlantic, nevertheless, continued to conspire to bring back a constitutional monarchy, ultimately succeeding in 1820. The most dramatic example of transatlantic collaboration is perhaps Francisco Javier Mina's expedition to Texas and northern Mexico in 1816 and 1817. Spanish Americans in royalist areas who were committed to independence had already joined the guerrilla movements. However, Ferdinand's actions did set areas outside of the control of the crown on the path to full independence.
=== Disease-modifying agents === Disease-modifying antirheumatic drugs (DMARDs) are the primary treatment for RA. They are a diverse collection of drugs, grouped by use and convention. They have been found to improve symptoms, decrease joint damage, and improve overall functional abilities. DMARDs should be started early in the disease as they result in disease remission in approximately half of people and improved outcomes overall. The following drugs are considered DMARDs: methotrexate, sulfasalazine, leflunomide, hydroxychloroquine, TNF inhibitors (certolizumab, adalimumab, infliximab and etanercept), abatacept, anakinra, and auranofin. Additionally, rituximab and tocilizumab are monoclonal antibodies and are also DMARDs. Use of tocilizumab is associated with a risk of increased cholesterol levels. The most commonly used agent is methotrexate, with other frequently used agents including sulfasalazine and leflunomide. Leflunomide is effective when used for 6–12 months, with similar effectiveness to methotrexate when used for 2 years. Sulfasalazine also appears to be most effective in the short-term treatment of rheumatoid arthritis. Hydroxychloroquine, in addition to its low toxicity profile, is considered effective for the treatment of moderate RA symptoms. Pharmacokinetic characteristics of Hydroxychloroquine are complex due to the large volume of distribution, significant tissue binding, and long terminal elimination half-life.
Sources: en.wikipedia.org
=== Copper toxicity === The classic copper-catalyzed azide-alkyne cycloaddition has been an extremely fast and effective click reaction for bioconjugation, but it is not suitable for use in live cells due to the toxicity of Cu(I) ions. Toxicity is due to oxidative damage from reactive oxygen species formed by the copper catalysts. Copper complexes have also been found to induce changes in cellular metabolism and are taken up by cells. There has been some development of ligands to prevent biomolecule damage and facilitate removal in in vitro applications. However, it has been found that different ligand environments of complexes can still affect metabolism and uptake, introducing an unwelcome perturbation in cellular function.
== Vaccination Campaign == On 13 November, the government of Sudan requested help from the International Coordinating Group on Yellow Fever Vaccine Provision (YF-ICG) in starting a mass vaccination campaign. Besides the WHO, the YF-ICG consists of representatives of the United Nations Children's Fund (UNICEF), Médecins sans Frontières (MSF) and the International Federation of Red Cross and Red Crescent Societies (IFRC). The United Nations–African Union Mission in Darfur (UNAMID) airlifted the first batches of vaccines from Khartoum to Darfur on 18 November. Mass vaccination began on 20 November. Efforts were also undertaken to eliminate mosquitoes. A team from the Naval Medical Research Unit Three (NAMRU-3) and the WHO Collaborating Center was deployed from Cairo to help collect and test samples and train local personnel. The vaccination campaign, from late November 2012 through early January 2013, covered more than 3 million people and halted the outbreak. A new phase of the campaign beginning in January covered more than 2 million more people at risk. One of the difficulties was maintaining a cold chain for vaccine viability while transporting vaccine by donkey into remote areas. A situation report released on 10 January 2013 reported that 171 people had died of the disease as of 9 January 2013. The number of suspected cases since 2 September 2012 was 847. The Minister of Health had announced on 5 January that no additional cases had appeared in the previous 3 weeks.
== Regulation by the photoperiod == The levels of proopiomelanocortin (pomc) are regulated indirectly in some animals by the photoperiod. It is referred to the hours of light during a day and it changes across the seasons. Its regulation depends on the pathway of thyroid hormones that is regulated directly by the photoperiod. An example are the siberian hamsters who experience physiological seasonal changes dependent on the photoperiod. During spring in this species, when there is more than 13 hours of light per day, iodothyronine deiodinase 2 (DIO2) promotes the conversion of the prohormone thyroxine (T4) to the active hormone triiodothyronine (T3) through the removal of an iodine atom on the outer ring. It allows T3 to bind to the thyroid hormone receptor (TR), which then binds to thyroid hormone response elements (TREs) in the DNA sequence. The pomc proximal promoter sequence contains two thyroid-receptor 1b (Thrb) half-sites: TCC-TGG-TGA and TCA-CCT-GGA indicating that T3 may be capable of directly regulating pomc transcription. For this reason during spring and early summer, the level of pomc increases due to the increased level of T3. However, during autumn and winter, when there is less than 13 hours of light per day, iodothyronine desiodinase 3 removes an iodine atom which converts thyroxine to the inactive reverse triiodothyronine (rT3), or which converts the active triiodothyronine to diiodothyronine (T2). Consequently, there is less T3 and it blocks the transcription of pomc, which reduces its levels during these seasons.
Sources: en.wikipedia.org
== See also == Interactome Protein–protein interaction Protein function prediction Protein structure prediction Protein structure prediction software Gene prediction Macromolecular docking Protein–DNA interaction site predictor Two-hybrid screening FastContact
=== Cuticular color === Cuticular color (pigmentation of the cuticle) is a heritable component and varies from tan to black. In the mealworm beetle, evidence suggests that population level variation in cuticular color is linked to pathogen resistance in that darker individuals are more resistant to pathogens. A study found that two immune parameters related to resistance, haemocyte density and pre-immune challenge activity of phenoloxidase, were significantly higher in selection lines of black beetles compared to tan lines. Higher haemocyte density is likely indicative of a heightened immune response. There were no effects of gender on the immune traits. Cuticular color is dependent on melanin production, which requires phenoloxidase, an enzyme that is present in its inactive form inside haemocytes. This shows why darker insects have a heightened immune response and are more resistant to pathogens that invade the hemocoel via the cuticle. However, there was no significant difference in haemolymph antibacterial activity between black and tan lines, explained by how antimicrobial peptides are produced by haemocytes but are not involved in cuticular darkening. In T. molitor, the degree of cuticular melanization is a strong indicator of resistance to the entomopathogenic fungus Metarhizium anisopliae, which could be explained by the thicker and less porous cuticle displayed by darker insects compared to lighter ones.
==== Physical examination ==== Blinded weight: The patient will strip and put on a surgical gown alone. The patient will step backwards onto the scale as the healthcare provider blocks the reading from the patient's line of vision. Orthostatic vitals: The patient lies completely flat for five minutes, and then, the medical provider measures the patient's blood pressure and heart rate. The patient stands up and stays stationary for two minutes. Then, the blood pressure and heart rate are assessed again, making note of any patient symptoms upon standing like dizziness. According to the College of Family Physicians of Canada, a change in orthostatic heart rate greater than 20 beats/minute or a change in orthostatic blood pressure greater than 10mmHg can warrant admission for an adolescent. Examination of hands and arms for brittle nails, Russell's sign, swollen joints, lanugo, and self harm. Auscultation of the chest for rubs, gallops, thrills, murmurs, and apex beat. Examination of the face for puffiness, dental decay, swollen parotid glands, and conjunctival hemorrhage.
Abdul Basit, senior associate fellow at the International Centre for Political Violence and Terrorism Research (ICPVTR), stressed that the concern was not the drones' sophistication, but their presence in Pakistan's capital. Taliban drones forced airspace closures and targeted deep within the country, escalating the threat both horizontally and vertically. Hammad Waleed, a research associate at Pakistan's Strategic Vision Institute, stated that while Pakistan's air defense could counter numbered drone projectiles, it would struggle against drone swarms.
Sources: en.wikipedia.org
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.
It is classified as a PPARδ agonist on the WADA Prohibited List. Anti-doping laboratories can detect it and its metabolites in urine. Its use is banned in competition and usually out of competition.
Rodent studies reported increased tumor incidence at multiple sites. The human relevance remains uncertain, but the findings contributed to discontinuation of development. No long-term human cancer data are available.
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.